BCAL Diagnostics (ASX:BDX) Accounts Payable: A$0.74 Mil (As of Dec. 2025)


What is BCAL Diagnostics Accounts Payable?

BCAL Diagnostics ASX:BDX +1.39% Accounts Payable is A$0.74 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's Accounts Payable for the quarter that ended in Dec. 2025 was A$0.74 Mil.

BCAL Diagnostics's quarterly Accounts Payable declined from Dec. 2024 (A$0.75 Mil) to Jun. 2025 (A$0.55 Mil) but then increased from Jun. 2025 (A$0.55 Mil) to Dec. 2025 (A$0.74 Mil).

BCAL Diagnostics's annual Accounts Payable declined from Jun. 2023 (A$1.58 Mil) to Jun. 2024 (A$0.74 Mil) and declined from Jun. 2024 (A$0.74 Mil) to Jun. 2025 (A$0.55 Mil).

BCAL Diagnostics Accounts Payable Related Terms

BCAL Diagnostics Accounts Payable Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Accounts Payable Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Accounts Payable
0.28 1.58 0.74 0.55

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 0.74 0.75 0.55 0.74

BCAL Diagnostics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$0.74 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Accounts Payable of A$0.74 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Accounts Payable too high?
BCAL Diagnostics' current Accounts Payable is A$0.74 Mil.
How does BCAL Diagnostics' Accounts Payable compare to TMO and DHR?
BCAL Diagnostics' Accounts Payable of A$0.74 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Diagnostics & Research company?
A good Accounts Payable depends on the Medical Diagnostics & Research industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Accounts Payable is A$0.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Accounts Payable of A$0.74 Mil. The current Accounts Payable is A$0.74 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Accounts Payable is A$0.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.